anthonyyazdaniml/gliner-biomed-curated-corpus huggingface dataset:
Risk Summary

There are no available data with the use of fesoterodine fumarate in pregnant women and adolescents to evaluate for a drug-associated risk of major birth defects, miscarriage or adverse maternal or fetal outcomes. In animal reproduction studies, oral administration of fesoterodine to pregnant mice and rabbits during organogenesis resulted in fetotoxicity at maternal exposures that were 6 and 3 times respectively the maximum recommended human dose (MRHD) of 8 mg/day, based on AUC (see Data). The background risk of major birth defects and miscarriage for the indicated population are unknown. However, in the U.S. general population, the estimated background risk of major birth defects and miscarriage in clinically recognized pregnancies is 2 to 4% and 15 to 20%, respectively.

Data

Animal Data 

No dose-related teratogenicity was observed in reproduction studies performed in mice and rabbits. In mice at 6 to 27 times the expected exposure at the maximum recommended human dose (MRHD) of 8 mg based on AUC (75 mg/kg/day, oral), increased resorptions and decreased live fetuses were observed. One fetus with cleft palate was observed at each dose (15, 45, and 75 mg/kg/day), at an incidence within the background historical range. In rabbits treated at 3 to 11 times the MRHD (27 mg/kg/day, oral), incompletely ossified sternebrae (retardation of bone development) and reduced survival were observed in fetuses. In rabbits at 9 to 11 times the MRHD (4.5 mg/kg/day, subcutaneous), maternal toxicity and incompletely ossified sternebrae were observed in fetuses (at an incidence within the background historical range). In rabbits at 3 times the MRHD (1.5 mg/kg/day, subcutaneous), decreased maternal food consumption in the absence of any fetal effects was observed. Oral administration of 30 mg/kg/day fesoterodine to mice in a pre- and post-natal development study resulted in decreased body weight of the dams and delayed ear opening of the pups. No effects were noted on mating and reproduction of the F1 dams or on the F2 offspring.
A system and method for facilitating dynamic biometric measurement is disclosed. In particular, the system may include a garment to be worn on the body of the user. The garment may include a flexible circuit upon which a plurality of sensor arrays and a processing unit may be disposed upon. Once activated, the sensors of the plurality of sensor arrays may continuously measure sensor data associated with the user, such as when the user is at rest and when the user in motion. The sensors may transmit signals including the sensor data to the processing unit for aggregation, processing, and filtration. The processing unit may also analyze the sensor data to determine a physiological condition of the user, a health condition of the user, a state of the user, or a combination thereof. The analyzed sensor data may be transmitted to a device for presentation, further processing, and storage.
BACKGROUND/OBJECTIVES: Obesity impairs intestinal glucose uptake (GU) (intestinal uptake of circulating glucose from blood) and alters gut microbiome. Exercise improves intestinal insulin-stimulated GU and alters microbiome. Genetics influence the risk of obesity and gut microbiome. However, the role of genetics on the effects of exercise on intestinal GU and microbiome is unclear.
METHODS: Twelve monozygotic twin pairs discordant for BMI (age 40.4 ± 4.5 years, BMI heavier 36.7 ± 6.0, leaner 29.1 ± 5.7, 8 female pairs) performed a six-month-long training intervention. Small intestine and colonic insulin-stimulated GU was studied using [18F]FDG-PET and microbiota from fecal samples with 16s rRNA.
RESULTS: Ten pairs completed the intervention. At baseline, heavier twins had lower small intestine and colonic GU (p < 0.05). Response to exercise differed between twins (p = 0.05), with leaner twins increasing colonic GU. Alpha and beta diversity did not differ at baseline. During the intervention, beta diversity changed significantly, most prominently at the mid-point (p < 0.01). Beta diversity changes were only significant in the leaner twins when the twin groups were analyzed separately. Exercise was associated with changes at the phylum level, mainly at the mid-point (pFDR < 0.05); at the genus level, several microbes increased, such as Lactobacillus and Sellimonas (pFDR < 0.05). In type 1 analyses, many genera changes were associated with exercise, and fewer, such as Lactobacillus, were also associated with dietary sugar consumption (p < 0.05).
CONCLUSIONS: Obesity impairs insulin-stimulated intestinal GU independent of genetics. Though both twin groups exhibited some microbiota changes, most changes in insulin-stimulated colon GU and microbiota were significant in the leaner twins.
Infuse paclitaxel (75mg/m\^2) and cisplatin (75mg/m\^2) at 43℃ through the two drainage tubes placed in the upper abdomen, using the two drainage tubes placed in the lower abdomen as the effluent tubes, with an infusion time of 90 minutes and an infusion rate of 500-600 mL/min. The first HIPEC with paclitaxel should be performed within 24 hours after cytoreductive surgery. The second HIPEC with cisplatin should be performed 24 hours after the completion of the first HIPEC. Intravenous sedatives such as diazoxide, or propofol at 2-6 ml/h should be administered during HIPEC treatment with continuous intravenous infusion by a pump，or intramuscular injection of 50 mg of pethidine.
FIELD: medicine. SUBSTANCE: method includes exposure of body parts (palms of hands or feet of legs) to radiation of microorganisms, class H. halobium contained in sea water. Device has radiation source which is airtight vessel made of nonmetallic material and filled with sea water containing microorganisms of class H. halobium. Vessel is placed in body consisting of several casings made of nonmetallic material. EFFECT: more effective treatment of inflammatory processes of different origin. 2 cl, 2 ex, 1 dwg
Patients complete a physical function test over 15 minutes at baseline, and at days 14, 28, and 56. Patients also participate in an 8-week home-based strengthening and walking program consisting of a strengthening/resistance program for 30 minutes, 3 times a week, and walking program for 20-30 minutes at least 3 times a week.
With the increasing prevalence of microplastics (MPs) in the environment, human health has become a growing concern. After entering the human body, MPs accumulate in the kidneys, indicating that the kidneys are their major target organs. This study investigated nephrotoxicity associated with MPs, with a specific focus on polystyrene (PS) MPs and amino-functionalized polystyrene (PS-NH2) MPs. Although previous studies have documented the nephrotoxic effects associated with short-term exposure to MPs, the mechanisms of kidney toxicity caused by chronic long-term exposure to MPs remain largely unclear. In animal models, mice were exposed to MPs (10 mg/L) at concentrations that are accessible to humans, administered via drinking water over a period of six months. These findings indicate that MPs can induce renal fibrosis by facilitating the onset of inflammation and accumulation of a substantial number of inflammatory cells. Our in vitro study showed that long-term exposure to MPs (60 μg/mL) induced ferroptosis in renal tubular epithelial cells via ferritinophagy and secreted TGF-β1, leading to renal fibroblast activation. Conversely, the application of Fer-1, a ferroptosis inhibitor, prevents ferroptosis in renal epithelial cells and reverses the activation of renal fibroblasts. Our study identified a novel toxicity mechanism for renal fibrosis induced by MPs exposure, offering new insights into the detrimental effects of environmental MPs on human health.
Osimertinib is a first-line or adjuvant therapy for non-small cell lung cancer (NSCLC) harboring an epidermal growth factor receptor (EGFR) mutation. However, owing to the adverse events associated with treatment, certain patients cannot maintain a daily regimen of 80 or 40 mg. In this study, we examined the efficacy of 40 mg of osimertinib administered every other day. In this single-center, retrospective study, we evaluated patients with NSCLC harboring an EGFR mutation in whom treatment was initiated with 40 mg osimertinib every other day at our institution between May 2016 and June 2023. The major outcome was the duration of administering 40 mg osimertinib every other day. Six patients with NSCLC were evaluated. The median duration of 40 mg osimertinib intake every other day was 12.6 months. Four of the six patients weighed below 50 kg, and four experienced weight loss. Additionally, four of the six patients had severe renal impairment upon receiving 40 mg osimertinib every other day. Thus, our findings suggest the efficacy of administering 40 mg osimertinib every other day in patients with low bodyweight, weight loss, or severe renal impairment.
The invention discloses a functional polypeptide, an erythrocyte medicine carrying system capable of specifically combining collagen and application thereof. The functional polypeptide comprises a collagen binding sequence and an erythrocyte binding peptide sequence linked to the collagen binding sequence. The functional polypeptide has an amino acid sequence shown in SEQ ID NO. 1. The erythrocyte medicine carrying system capable of being specifically combined with collagen comprises medicine carrying erythrocytes and functional polypeptide specifically combined with the medicine carrying erythrocytes. The erythrocyte medicine carrying system capable of specifically combining collagen constructed by the invention can effectively anchor medicine carrying erythrocyte microspheres on collagen materials, reduces the rapid loss of medicines after transplantation, has the capacity of realizing the concentration maintenance and slow release of medicines at the damaged part, can prolong the half life of the medicines, promotes more neural stem cells to differentiate towards neurons, promotes more axon regeneration, and has the function of promoting better movement recovery of spinal cord injury.
INTRODUCTION: Otitis media (middle ear disease) severity and chronicity among Aboriginal and Torres Strait Islander people, as well as gaps in socioeconomic outcomes related to hearing loss, indicates a breakdown in the current ear and hearing care system. The ear and hearing care system spans multiple sectors due to long-term impacts of otitis media and hearing loss in health, education and employment, necessitating a multi-disciplinary cross-sectorial approach to ear and hearing care. Public policies shape the current ear and hearing care system and here it is argued that a critical public policy analysis across different sectors is needed, with strong Aboriginal and Torres Strait Islander leadership and guidance. The current study aims to establish consensus-based ear and hearing care policy solutions for Aboriginal and Torres Strait Islander people in Australia.
METHODS AND ANALYSIS: This multi-method study will be guided by a Brains Trust with strong Aboriginal and Torres Strait Islander leadership. Public policies in hearing health, social services, and education will be scoped to identify policy gaps, using the World Health Organization framework. Qualitative data will be collected through a culturally specific process of yarning circles to identify policy challenges and/or limitations in enabling accessible ear and hearing care programs/services for Aboriginal and Torres Strait Islander people, using dimensions of Morestin's public policy appraisal tool as an interview guide for stakeholders. Themes from the yarning circles will be used to inform an expert Delphi process to establish consensus-based policy solutions for optimising the ear and hearing care system for Aboriginal and Torres Strait Islander people.
ETHICS AND DISSEMINATION: This study has approval from the Australian Institute of Aboriginal and Torres Strait Islander Studies Ethics Committee. Study findings will be disseminated to community through Brains Trust members and study participants, as well as through publications in peer-reviewed journals and research forum presentations.
Chronic Kidney Disease (CKD) is a major burden of public health affecting millions of people around the world. It is rising in prevalence with high public health costs and is associated with a high degree of morbidity and mortality. Here, the inventors determined whether the exchange protein directly activated by cAMP 1 (Epac1) contributed to severe glomurelonephritis (GN) induced by injecting nephrotoxic serum (NTS) in mice. Treatment of GN mice with a pharmacological activator of Epacl, 8-(4-Chlorophenylthio)-2'-O-methyladenosine-3', 5'- cyclic monophosphate (8-pCPT) improved functional and structural renal parameters, and reduced renal inflammation after NTS injection. Taken together, these findings suggest that Epacl activation is an attractive and promising pharmacological intervention for the therapeutic treatment of CKD. Thus the present invention relates to use of Epac1 activators for the treatment of chronic kidney diseases..
The ongoing expansion of human genomic datasets propels therapeutic target identification; however, extracting gene-disease associations from gene annotations remains challenging. Here, we introduce Mantis-ML 2.0, a framework integrating AstraZeneca's Biological Insights Knowledge Graph and numerous tabular datasets, to assess gene-disease probabilities throughout the phenome. We use graph neural networks, capturing the graph's holistic structure, and train them on hundreds of balanced datasets via a robust semi-supervised learning framework to provide gene-disease probabilities across the human exome. Mantis-ML 2.0 incorporates natural language processing to automate disease-relevant feature selection for thousands of diseases. The enhanced models demonstrate a 6.9% average classification power boost, achieving a median receiver operating characteristic (ROC) area under curve (AUC) score of 0.90 across 5220 diseases from Human Phenotype Ontology, OpenTargets, and Genomics England. Notably, Mantis-ML 2.0 prioritizes associations from an independent UK Biobank phenome-wide association study (PheWAS), providing a stronger form of triaging and mitigating against underpowered PheWAS associations. Results are exposed through an interactive web resource.
Diabetic patients consume over 10% of health care costs in most developed countries. Over 80% of these resources are used to treat diabetic complications and late stage diseases. Over 30% of patients admitted to the medical wards in Hong Kong's public hospitals have diabetes, mainly due to cardiovascular and renal complications. Diabetes is now the leading cause of end stage renal disease (ESRD), accounting for 30-50% of patients on renal replacement therapy (RRT). In Hong Kong, the number of patients receiving RRT have increased by 50% in the last 5 years but the number of patients with ESRD due to diabetes have doubled. Between 10% and 15% of patients attending medical clinics in local public hospitals either receive insulin or anti-diabetic drugs. In both community and hospital settings, between 30% and 50% of diabetic patients have albuminuria, which is by far the most powerful predictor for early mortality, cardiovascular morbidity and renal disease. Local published data show that 3-10% of diabetic patients died or developed clinical endpoints yearly.

There are now overwhelming evidence supporting the beneficial effects of optimal control of cardiovascular risk factors on clinical outcomes in diabetic patients. However, there are few studies to examine the most effective way to translate these scientific evidence collected in closely monitored clinical trial situations into daily clinical practice. Results from this multi-centre, randomized study will provide important information to health care policy makers regarding the cost effectiveness of disease management using a multidisciplinary team to deliver a structured care model in light of the growing diabetes epidemic and the constraints of finite resources and the need for equity.
Abemaciclib 150 milligram (mg) administered orally every 12 hours on Days 1 to 28 of a 28-day cycle in combination with fulvestrant 500mg administered intramuscularly (IM) on Days 1 and 15 of Cycle 1, then on Day 1 of Cycle 2 and beyond. Participants received treatment until discontinuation were met.
his invention concerns the method of production and the application of new water soluble polymer agents (complexes) of sorbic acid, Nystatine and amphotericine B. The composition of the above products is effected by their reaction with polyvinylpyrrolidone (PVP) of different molecular weights. The complexes of sorbic acid have the following chemical structure:[*]Complexes of nystatine, amphotericine B and azoles with PVP have the same chemical structure. The antimycosis activity of the complexes produced was certified in-vitro to potentially pathogenic (Fusarium oxysporum) as well as pathogenic for humans and animals nycetes (Aspergillus parasiticus, Penicillium viridicatum, Candida tropicalis and Candida albicans). It was observed that the biological activity is a function of their molecular weight and that activity increased as the molecular weight was reduced. Water solubility, biocompatibility and proven better biological activity relatively to the micromolecular substances are among the principal features of the polymer medicines.
The invention relates to a toothpaste and a preparation method thereof, belonging to the field of articles for daily use. The toothpaste comprises the following ingredients: rubbing agent, humectant, thickening agent, surface active agent, sweetening agent, essence, water, color agent and buckwhaet flavonoids; wherein, the rubbing agent, the humectant, the thickening agent, the surface active agent, the sweetening agent, the essence, the water and the buckwhaet flavonoids respectively have the weight percentage of 10-50:10-60:0.1-5:0-5:0.1-1:0.1-2:5-30:0.1-5. The invention also comprises the method for preparing the toothpaste. The invention also discloses a method for preparing the toothpaste. The toothpaste and the preparation method thereof have the technical proposal that by being added with the buckwhaet flavonoids, the toothpaste has the advantages of improving the oral cavity microorganism environment, keeping oral smell fresh, preventing and improving stomatitis such as ngivitis and the like, strengthening oral cavity to prevent various inflammations, etc. The toothpaste especially has the effects of diminishing inflammation and relieving pain, inhibiting disease germ, and improving periodontitis, gingival dleeding, canker sore, etc.
Patients treated with cardiac stereotactic body radiation therapy (radioablation) for refractory ventricular arrhythmias are patients with advanced structural heart disease and significant comorbidities. However, data regarding 1-year mortality after the procedure are scarce. This systematic review and pooled analysis aimed at determining 1-year mortality after cardiac radioablation for refractory ventricular arrhythmias and investigating leading causes of death in this population. MEDLINE/EMBASE databases were searched up to January 2023 for studies including patients undergoing cardiac radioablation for the treatment of refractory ventricular arrhythmias. Quality of included trials was assessed using the NIH Tool for Case Series Studies (PROSPERO CRD42022379713). A total of 1,151 references were retrieved and evaluated for relevance. Data were extracted from 16 studies, with a total of 157 patients undergoing cardiac radioablation for refractory ventricular arrhythmias. Pooled 1-year mortality was 32 % (95 %CI: 23-41), with almost half of the deaths occurring within three months after treatment. Among the 157 patients, 46 died within the year following cardiac radioablation. Worsening heart failure appeared to be the leading cause of death (52 %), although non-cardiac mortality remained substantial (41 %) in this population. Age≥70yo was associated with a significantly higher 12-month all-cause mortality (p<0.022). Neither target volume size nor radiotherapy device appeared to be associated with 1-year mortality (p = 0.465 and p = 0.199, respectively). About one-third of patients undergoing cardiac stereotactic body radiation therapy for refractory ventricular arrhythmias die within the first year after the procedure. Worsening heart failure appears to be the leading cause of death in this population.
CAS is first treated with conventional plain balloon angioplasty. Once treated adequately (\<30% residual stenosis), CAS will be treated with PCB first to avoid geographical miss. After which, stent graft will be deployed. Length of PCB shall be long enough to cover stent edges.
PURPOSE: A novel glucosinolate compound isolated from broccoli is provided to ensure antioxidation and anti-bacterial activity and to prevent or treat diseases caused by pathogenic microbial infection. CONSTITUTION: A glucosinolate compound(6'-O-trans- (4"-hydroxycinnamoyl)-4-(methylsulfinyl)butyl glucosinolate) is denoted by chemical formula 1. The compound is isolated from broccoli. Broccoli extract with antioxidation and anti-bacterial activity contains the compound of chemical formula 1 as an active ingredient. The extract is prepared by adding 2-15 time amount of solvent to broccoli and heating at 70-130°C. The solvent includes water, low carbon number alcohol of C1-C4, acetone, or solution thereof. A pharmaceutical composition for antioxidation and anti-bacterial activity contains the compound of chemical formula 1 or extract as an active ingredient.
The invention relates to an ethylene oxide modified coleus forskohlii oil antibacterial agent and a preparation method thereof. The preparation method comprises the following step of carrying out ring-opening polymerization reaction of hydroxyl groups in coleus forskohlii oil and ethylene oxide in the presence of boron trifluoride diethyl ether as a catalyst. The preparation method has the advantages of simple synthetic route, low reaction temperature and short reaction time. The prepared modified coleus forskohlii oil antibacterial agent has the characteristics of good water solubility, strong antibacterial capability, broad antibacterial spectrum, long shelf life and good safety, and good antibacterial property of the coleus forskohlii oil is maintained. The antibacterial agent can be widely used in bacteriostat and anticorrosion of products such as shampoo, shower gel, liquid soap, laundry detergent, cosmetics lotion and wet wipes. An effective addition amount of the antibacterial agent accounts for 1.0-5.0% of total mass of the product.
Negative health consequences of obesity include impaired neuronal functioning and cell death, thus bringing the risk of impaired cognitive functioning. Antioxidant properties of polyphenols offer a possible intervention for overweight people, but evidence for their effectiveness in supporting cognitive functioning is mixed. This review examined evidence from randomized controlled trials concerning the effect of polyphenols on tasks requiring either immediate or delayed retrieval of learned information, respectively, thus controlling for differences in cognitive processes and related neural substrates supporting respective task demands. Searches of the PubMed/Medline, PsycInfo, and Scopus databases identified 24 relevant primary studies with N = 2336 participants having a BMI ≥ 25.0 kg/m2. The participants' mean age for the 24 studies exceeded 60 years. Respective meta-analyses produced a significant summary effect for immediate retrieval but not for delayed retrieval. The present findings support a potential positive effect of chronic supplementation with polyphenols, most notably flavonoids, on immediate retrieval in participants aged over 60 years with obesity being a risk factor for cognitive impairment. We recommend further investigation of this potential positive effect in participants with such risk factors. Future research on all populations should report the phenolic content of the supplementation administered and be specific regarding the cognitive processes tested.